rs769554577
Variant summary
Our verdict is Uncertain significance. Variant got 2 ACMG points: 2P and 0B. PP3_Moderate
The NM_001406875.1(PMS2):c.-288T>C variant causes a 5 prime UTR premature start codon gain change. The variant allele was found at a frequency of 0.0000281 in 1,603,236 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_001406875.1 5_prime_UTR_premature_start_codon_gain
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 2 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000460 AC: 7AN: 152200Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000160 AC: 4AN: 250710Hom.: 0 AF XY: 0.0000147 AC XY: 2AN XY: 135644
GnomAD4 exome AF: 0.0000262 AC: 38AN: 1451036Hom.: 0 Cov.: 27 AF XY: 0.0000249 AC XY: 18AN XY: 722604
GnomAD4 genome AF: 0.0000460 AC: 7AN: 152200Hom.: 0 Cov.: 32 AF XY: 0.0000404 AC XY: 3AN XY: 74344
ClinVar
Submissions by phenotype
not provided Uncertain:4
- -
The PMS2 c.197T>C (p.Ile66Thr) variant has been reported in the published literature in individuals with colorectal cancer (PMID: 27435373 (2016)), breast cancer (PMID: 33471991 (2021), https://databases.lovd.nl/shared/), and an undisclosed cancer type (PMID: 31391288 (2020)). Additionally, this variant has been identified in reportedly healthy individuals (PMID: 33471991 (2021); https://databases.lovd.nl/shared/, 36243179 (2022)). An in vitro analysis of this variant showed partially decreased PMS2 mismatch repair binding (PMID: 27435373 (2016)). The frequency of this variant in the general population, 0.000023 (3/128716 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is uninformative in the assessment of its pathogenicity. Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is damaging. Based on the available information, we are unable to determine the clinical significance of this variant. -
PMS2: PM2, PS3:Supporting, BP1 -
Demonstrated to have proficient mismatch repair efficiency in an in vitro assay (PMID: 27435373); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 34172528, 11574484, 36243179, 27435373, 32980694) -
Lynch syndrome 4 Uncertain:4
This variant is classified as a variant of uncertain significance as there is insufficient evidence to determine its impact on protein function and/or cancer risk. -
- -
- -
The PMS2 c.197T>C (p.Ile66Thr) missense change has a maximum subpopulation frequency of 0.005% in gnomAD v2.1.1 (https://gnomad.broadinstitute.org/). The in silico tool REVEL predicts a deleterious effect on protein function and a functional study investigating mismatch repair proficiency demonstrated that this variant has intermediate relative repair efficiency compared to the wild-type (PMID: 27435373). This variant has been reported in an individual with colorectal cancer whose tumor showed weak PMS2 staining on immunohistochemistry and did not show microsatellite instability (PMID: 27435373). In summary, the evidence currently available is insufficient to determine the clinical significance of this variant. It has therefore been classified as of uncertain significance. -
Hereditary cancer-predisposing syndrome Uncertain:2
The p.I66T variant (also known as c.197T>C), located in coding exon 3 of the PMS2 gene, results from a T to C substitution at nucleotide position 197. The isoleucine at codon 66 is replaced by threonine, an amino acid with similar properties. This alteration has been detected in a Dutch individual with colorectal cancer diagnosed at age 47 whose tumor showed low microsatellite instability (MSI-L) and weak PMS2 staining on immunohistochemical analysis, and this alteration was found to have somewhat reduced mismatch repair activity compared to the wildtype PMS2 protein (van der Klift HM et al. Hum. Mutat. 2016 Nov;37:1162-1179). This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
This missense variant replaces isoleucine with threonine at codon 66 of the PMS2 protein. Computational prediction tools and conservation analyses suggest that this variant may have deleterious impact on the protein function. This variant has been reported in individuals affected with colorectal cancer (PMID: 27435373, 34172528). A functional study showed that the variant protein had intermediate activity in an in vitro mismatch repair assay (PMID: 27435373). This variant has been identified in 6/282110 chromosomes in the general population by the Genome Aggregation Database (gnomAD) and has been reported in healthy individuals (PMID: 32980694). Available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
Breast and/or ovarian cancer Uncertain:1
- -
Lynch syndrome Uncertain:1
This missense variant replaces isoleucine with threonine at codon 66 of the PMS2 protein. Computational prediction tools and conservation analyses suggest that this variant may have deleterious impact on the protein function. This variant has been reported in individuals affected with colorectal cancer (PMID: 27435373, 34172528). A functional study showed that the variant protein had intermediate activity in an in vitro mismatch repair assay (PMID: 27435373). This variant has been identified in 6/282110 chromosomes in the general population by the Genome Aggregation Database (gnomAD) and has been reported in healthy individuals (PMID: 32980694). Available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
Hereditary nonpolyposis colorectal neoplasms Benign:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at